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ABSTRACT
OBJECTIVE To compare guidelines (not the primary studies) for pharmacologic treatment of migraine as to methods of 
guideline development; recommendations, particularly on triptans; and quality of supporting evidence (with emphasis on 
comparative studies of triptans versus ergot alkaloids and nonsteroidal anti-inflammatory drugs [NSAIDs]).
DATA SOURCES We searched MEDLINE via PubMed for guidelines on migraine management published since 1990 in any 
language; in addition, we browsed the Internet for information.
STUDY SELECTION We found nine clinical guidelines on migraine; one guideline, not supported by references, was excluded. 
SYNTHESIS Preference for triptans is not well founded and is largely based on comparisons with placebo. Too few studies 
compared new drugs with established ones (NSAIDs or dihydroergotamine). Guidelines that propose a hierarchy for selection 
of drugs are opinion-based rather than evidence-based.
CONCLUSION The current lack of evidence from comparative studies seriously limits development of evidence-based clinical 
practice guidelines for pharmacologic treatment of migraine.
RESUME
OBJECTIF Comparer les directives (et non les études primaires) concernant le traitement pharmacologique de la migraine, sous 
l'aspect particulier des méthodes de développement de ces directives, des recommandations émises, notamment pour les 
triptans, et de la qualité des preuves à l'appui (notamment pour les études comparant les triptans aux alcaloïdes de l'ergot et 
aux anti-inflammatoires non stéroïdiens [AINS]).
SOURCES DES DONNÉES On a utilisé PubMed pour identifier dans MEDLINE les directives publiées dans toutes les langues 
depuis 1990 sur le traitement de la migraine; on a également consulté Internet.
CHOIX DES ÉTUDES Neuf lignes directrices de pratique sur la m igraine ont été repérées; une directive sans support 
bibliographique a été exclue.
SYNTHÈSE La préférence pour les triptans n'est pas bien fondée, reposant principalement sur des comparaisons avec placebo. 
Trop peu d'études ont comparé les nouveaux médicaments aux médicaments traditionnels (AINS ou dihydroergotamine). Les 
directives préconisant un ordre de préférence pour les médicaments reposent sur des opinions plutôt que sur des preuves. 
CONCLUSION À l'heure actuelle, il n'y a pas assez d'études comparatives sur le traitement pharmacologique de la migraine 
pour permettre l'émission de lignes directrices de pratique fondées sur des preuves.
This article has been peer reviewed.
Cet article a fait l'objet d'une révision par des pairs. 
Can Fam Physician 2005;51:838-843.
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Several guidelines on diagnosis and treatment of migraine headache have been developed since the introduction of sumatriptan, the first drug 
in its class, around 1990. Until that time, ergot alka­
loids were known to be effective against migraine, 
and nonsteroidal anti-inflammatory drugs (NSAIDs) 
and acetaminophen were often prescribed.
Sumatriptan seemed to mark the beginning of 
a new period in migraine treatment. The efficacy 
of sumatriptan was self-evident, but by the time it 
was introduced, the essential question was whether 
the much more expensive sum atriptan was cost- 
effective compared with “simple” analgesics, such 
as acetam inophen, NSAIDs, or ergot alkaloids. 
Another issue was sumatriptan's safety for chronic 
use. This required studies that compared sumatrip­
tan with available (reference) medications, a general 
problem 1 in introducing new drugs. In com par­
ing migraine treatment guidelines published since 
1990, we were particularly interested in the role 
these guidelines defined for triptans and the evi­
dence to support this role (particularly in compar­
ing triptans with reference medications).
One problem for family physicians is that dif­
ferent guidelines deal with the same clinical topic. 
This can lead to information overload or even con­
flicting guidance. This is why we decided to com­
pare guidelines on migraine management.
Sources of information
In our systematic search for published guidelines 
on migraine treatment, we used MEDLINE through 
PubMed. The point of departure for the search was 
the occurrence of the word “migraine” in the title. 
In keeping with this, we specified that publications 
should include the key terms guideline, guidelines, 
or consensus and that the key term s pharm aco­
therapy or drug therapy had to occur. In view of the 
small number of publications, no limitations were
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applied with regard to the target group (first line) 
of the guidelines. As we were particularly inter­
ested in the position of triptans, we restricted the 
search to guidelines published after 1990.
In addition, we brow sed the In te rn e t via 
AltaVista using the terms "clinical guidelines,” "prac­
tice guidelines,” and "medical guidelines.” The web­
sites of institutes known to participate in guideline 
development were also searched. We also looked in 
a few relevant and recent reviews for references to 
other guidelines.
We summarized and subdivided recom menda­
tions found in the guidelines into first-, second-, and 
third-choice medications according to the guide­
lines or to our best judgment. Special emphasis 
was placed on the role of triptans and their posi­
tion in comparison with acetaminophen, NSAIDs, 
and ergot alkaloids.
Results
The search produced 32 articles; nine were clin­
ical guidelines for migraine management.2-10 We 
could not use one guideline because the recom ­
mendations were not supported by references.2 A 
summary of recommendations from the guidelines 
investigated is shown in Table 1.2-10 Some guide­
lines3,4,6,9 recommend a stepwise approach: acute 
attacks are treated initially with the safest, least 
expensive therapies with a switch to migraine- 
specific medication only if initial treatm ent fails. 
Stratified management, on the other hand, speci­
fies migraine severity and recommends migraine- 
specific agents for severe attacks.7
The remaining guidelines, 5,7,10 which do not make 
recommendations in order of preference, give each 
investigated drug a place based on all references. 
Table 12-10 shows medications in order of preference, 
partly as stated by the guidelines, 3,4,6,7,9 and partly (a 
somewhat arbitrary arrangement) according to our 
best judgm ent.5,8,10 Table 22-4,6-22 summarizes the 
position of triptans and (dihydro-)ergotamine in 
relation to NSAIDs and ergot alkaloids (only key 
studies are presented). There are few comparative 
studies; most recommendations mention the effec­
tiveness of sumatriptan among other triptans. Most
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guidelines, however, emphasize the lack of research not enable users to grade the quality of guide- 
on ergotamine and, to a lesser degree, dihydroer- lines. The guidelines we studied ranged from the 
gotamine. American guideline, which gives each investigated
drug a place based on all published studies, to the 
German guideline, which recommends a stepwise 
D is c u s s io n  approach with conventional medication but has
The guidelines we investigated differ greatly in only weak support for this recommendation. Use 
thoroughness and content. The AGREE instru- of levels of evidence is relatively common. The 
m en t23 is an in ternationally  accepted tool for guidelines that make no use of them 3,9,10 mostly 
assessing guidelines, bu t unfortunately it does discuss and evaluate the references they cite .3,10
Table 1. Summary of recommendations from investigated guidelines: Where no evidence is listed in the Table, none had been 
presented in the guideline.
G U ID E L IN E
FIR S T -C H O IC E  T R E A T M E N T  (L E V E L  OF 
EV ID EN C E)
SEC O N D -C H O IC E T R E A T M E N T  (L E V E L  OF 
EV ID E N C E )
T H IR D -C H O IC E T R E A T M E N T  (L E V E L  OF 
EV ID EN C E)
The Netherlands. NHG.3 (1999) Antiemetic combined with Antiemetic combined with NSAID Sumatriptan,
Stepwise approach acetaminophen or ASA ergotamine
The Netherlands. Quality-control 
committee of the Netherlands Society 
for Neurology.4 (1997)
Stepwise approach
Acetaminophen, ASA, or NSAID 
combined with an antiemetic if 
necessary
(I-III)
Sumatriptan (I) Ergotamine (I, III)
United States. American Academy of NSAIDs (ASA, ibuprofen, naproxen, Intranasal DHE (I) eg, naratriptan, Intranasal opiate (I) or intravenous
Family Physicians and American tolfenam ic acid, or a com bination) sumatriptan, antiemetic (II)
College of Physicians—American 
Society of Internal Medicine.6 (2002) 
Stepwise approach
(I, II) rizatriptan,
zolmitriptan
Germany. German Migraine and Antiemetic combined with ASA, Ergotamine, Sumatriptan
Headache Society.9 (1998) 
Stepwise approach
acetaminophen, or NSAID DHE
Canada. Canadian Headache Society.7 ASA (I), acetaminophen (III); NSAID NSAID (ibuprofen, naproxen, Intravenous antiemetic (I), NSAID
(1997) (ibuprofen, naproxen) (I); mefenamic acid) (I), sumatriptan (I), (ketorolac) (I), intravenous
Stratified approach antiemetic (III) DHE (I), ergotamine (II) phenothiazine (I),* sumatriptan (I), 
DHE (I), intranasal opiate (I), 
corticosteroid (II)
United States. US Headache Intravenous antiemetic (II), Ergotamine (II), NSAID (intramuscular Barbiturate (II, III), opiate (I),
Consortium.5 (2000) 
Without ranking
acetaminophen (II), NSAID (I, II) (ASA, 
ibuprofen, naproxen, tolfenamic acid), 
phenothiazine (II),* intranasal or 
subcutaneous DHE (I, II), sumatriptan 
(I), naratriptan (I), rizatriptan (I), 
zolmitriptan (I)
ketorolac) (II) corticosteroid (III)
Canada. Canadian Association of Intravenous antiemetic (I), Haloperidol (III), intranasal lidocaine
Emergency Physicians.8 (1999) intravenous phenothiazine (I),* NSAID (I), intranasal opiate (I), corticosteroid
(Only serious migraine emergency) 
Without ranking
(I), sumatriptan (I), DHE (II) (II)
Canada. Therapeutics Initiative.10 Acetaminophen, ASA, NSAID Intravenous antiemetic, DHE, opiate, intranasal sumatriptan
(1997) (ibuprofen, naproxen, diclofenac) phenothiazine,* DHE, NSAID
Without ranking combined with an antiemetic, oral 
sumatriptan
(ketorolac), subcutaneous 
sumatriptan, opiate
ASA— acetylsalicylic acid, DHE— dihydroergotamine, NHG— Netherlands College of General Practitioners, NSAID— nonsteroidal anti-inflammatory drug.
Levels of evidence: I— At least one properly conducted randomized controlled trial, systematic review, or meta-analysis; II— Other comparison trials or non-randomized cohort, case-control, or
epidemiologic studies, preferably with more than one study; III— Expert opinion or consensus statements. 
*  Not as an antiemetic.
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Orders of preference in guidelines3,4,9 are opinion- 
based, but this is not always m entioned . 3,9 One 
guideline7 classifies migraine headache on the 
basis of its severity without mentioning that this 
classification is not based on the reference stud­
ies. Another guideline6 mentions that the question
of which approach is best (stepwise or stratified 
management) is still unresolved .24,25
The place of tr ip ta n s  varies enorm ously  
(Table 12-10). This is at least remarkable, given the 
sparse international literature and the fact that all 
guidelines were based on (systematic) searches of
Table 2. Role of triptans: Comparative studies with NSAIDs and ergot alkaloids, and the role of (dihydro-)ergotamine.
G U ID E L IN E R E SU L T S  OF T R IA L S  (L E V E L  O F E V ID E N C E , W H E R E  G IV E N )
The Netherlands. NHG.3 
(1999)
Stepwise approach
The Netherlands. Quality- 
control committee of the 
Netherlands Society for 
Neurology.4 (1997)
Stepwise approach
United States. American 
Academy of Family 
Physicians and American 
College of Physicians— 
American Society of Internal 
Medicine.6 (2002)
Stepwise approach
Sumatriptan compared with:
• NSAIDs: equally effective11,12
• Ergotamine: sumatriptan more effective, but headaches recurred sooner13
• DHE: sumatriptan works somewhat faster, but headaches recurred sooner14
Ergotamine: effectiveness demonstrated15,16
Sumatriptan compared with other medications: records the small number of studies, not the conclusions12,13 (I)
Ergotamine and DHE: conclusions based mainly on clinical experience16,17 (II)
Oral sumatriptan compared with:
• NSAIDs: equally effective11,12,18 (I)
• Ergot or caffeine: sumatriptan more effective13 (I)
Subcutaneous sumatriptan compared with subcutaneous and intranasal DHE: sumatriptan more effective, but headaches recurred sooner14,19 (I) 
Intramuscular sumatriptan compared with intravenous chlorpromazine: equally effective20 (III)
Ergotamine: inconsistent results17 (III)
• Subcutaneous, intravenous, and intramuscular DHE: no studies demonstrate effectiveness as monotherapy21 (III)
• Intranasal DHE: less effective than subcutaneous sumatriptan19 (II)
• Subcutaneous DHE: after 3 hours equally effective as subcutaneous sumatriptan14 (I)
Oral sumatriptan compared with NSAIDs: not reviewed12_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Ergotamine and DHE: effectiveness mentioned but not supported22
Oral and subcutaneous sumatriptan compared with:
• NSAID: equally effective11 (I)
• DHE: sumatriptan more effective14 (I)_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Ergotamine: effectiveness not demonstrated17,22 (I)
Subcutaneous, intravenous, intramuscular, and intranasal DHE: effective14 (I)
Oral sumatriptan compared with ergotamine and caffeine: effective13 (I)
Subcutaneous sumatriptan compared with:
• Subcutaneous DHE: sumatriptan faster, but more recurrence of headaches14 (I)
• Intranasal DHE: sumatriptan more effective, but shorter acting19 (II)_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
DHE: few studies, no conclusions21 (III)
Intranasal DHE: effective19 (II)
Oral sumatriptan compared with ergotamine with caffeine and ASA: no visible difference11-13 
Subcutaneous sumatriptan compared with:
• Subcutaneous DHE: equally effective14
• Intranasal DHE: sumatriptan more effective19_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Ergotamine: effectiveness not demonstrated22
Intranasal DHE: effective19
ASA— acetylsalicylic acid, DHE— dihydroergotamine, NHG— Netherlands College of General Practitioners, NSAID— nonsteroidal anti-inflammatory drug.
Levels o f evidence: I— At least one properly conducted randomized controlled trial, systematic review, or meta-analysis; II— Other comparison trials or non-randomized cohort, case-control, 
or epidemiologic studies, preferably with more than one study; III— Expert opinion or consensus statements.
Germany. German Migraine 
and Headache Society.9 (1998) 
Stepwise approach
Canada. Canadian Headache 
Society.7 (1997)
Stratified approach
Canada. Canadian 
Association of Emergency 
Physicians.8 (1999)
(Only serious migraine 
emergency)
Without ranking
Canada. Therapeutics 
Initiative.10 (1997) 
Without ranking
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this literature. National medicopolitical differences 
might have a role here, as only a few guidelines 
consider costs in their recommendations.3,9 Given 
the many assumptions in the articles focusing on 
costs, it seems that cost-effectiveness calculations 
are somewhat theoretical.26,27
A factor tha t ham pers developm ent of high- 
quality guidelines for migraine treatm ent is that 
recently developed drugs, such as the triptans, have 
been the subject of more studies and more pub­
lications than old ones. Consequently, all guide­
lines list sum atriptan with supporting evidence. 
This, however, is evidence against placebo because 
there are only few comparisons with other effective 
drugs (Table 22-4,6-22). Recommendations on ergot 
alkaloids are, to a large extent, based on opinion or 
consensus.
Although the side effects of ergotamine (particu­
larly vasoconstriction, nausea, and vomiting) are 
well known, 16 triptans also have side effects (such 
as chest pain) .28,29 Lack of data on the relative long­
term safety of triptans has led to the conclusion 
that they are equal to the older drugs in terms of 
side effects. Again this is opinion, rather than evi­
dence-based information.
Limitations
This study was limited by the time frame chosen for 
selecting guidelines, but more information from 
recent reviews28-32 and results of studies compar­
ing sumatriptan and NSAIDs33,34 do not essentially 
change the findings of this study.
Conclusion
Guidelines should support medical practitioners in 
pursuing the highest quality of care for their patients. 
But family physicians who turn to the guidelines on 
migraine for support for pharmacotherapy will prob­
ably not find much help. Different guidelines recom­
mend different approaches, even when they are written 
for the same clinical care setting, such as primary care. 
Actual guideline-prescribed care will depend to a large 
extent on which guideline has been used. This intro­
duces an unsatisfactory element of chance.
EDITOR'S KEY POINTS
Family doctors frequently treat migraine headache, and there are 
numerous guidelines with recommendations for best care. The intro­
duction of triptans added a new but expensive alternative.
Some guidelines are based on an evaluation of the evidence, but 
ranking of treatments is som ewhat arbitrary and based on con­
sensus. This is because there are few trials comparing older treat­
ments with triptans.
Family doctors need to be aware of the lack of convincing evidence 
that triptans are more effective than older treatments.
POINTS DE REPERE DU REDACTEUR
Le m é d ecin  de fa m ille  d o it  so u ve n t tra ite r  des cé p h a lé e s  
m igra in e u se s et il existe  du nom breuses d irective s p récon i­
san t un tra ite m e n t de préférence à un autre. L 'introduction  
des t r ip t a n s  re p ré se n te  une o p tio n  n o u v e lle ,  q u o iq u e  
d ispendieuse.
Certaines d irectives reposent sur une évaluation des preuves, 
m ais l'établissem ent d'un ordre de préférence pour les tra ite ­
m ents est p lutôt arb itra ire  et relève du consensus. La raison 
en est qu'il y a peu d'études com parant les agents tra d itio n ­
nels aux triptans.
Le médecin de famille doit savoir qu'il y a peu de preuves convain­
cantes que les triptans sont supérieurs aux traitements traditionnels.
A comparison of the effectiveness and safety 
of all available migraine drugs, over all stages of 
migraine severity, would benefit family physicians. 
As long as these data are unavailable, guidelines 
will have little to offer. As long as new drugs are 
not tested before they are introduced in studies 
that compare their therapeutic value in the prac­
tical settings in which patients are usually treated, 
important information is unavailable to those who 
have to design guidelines. We would welcome a 
policy in which new medicines are accepted only 
when they have an evidence-based value over exist­
ing standard therapy. 0
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